Ironwood Pharmaceuticals Inc's Customers Performance

Name: Ironwood Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

IRWD

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


IRWD's Source of Revenues		During the corresponding time, Ironwood Pharmaceuticals Inc recorded a revenue increase by 32.62 % year on year, sequentially revenue grew by 6.14 %. While revenue at the Ironwood Pharmaceuticals Inc 's corporate clients • List of IRWD Customers

for the same period Ironwood Pharmaceuticals Inc recorded revenue increase by 32.62 % year on year, sequentially revenue grew by 6.14 %.

• List of IRWD Customers

Ironwood Pharmaceuticals Inc's Business Units


North America	191.1 %	of total Revenue
Europe and Other	1.7 %	of total Revenue
Collaborative Arrangement Collaboration and License Agreements	0.14 %	of total Revenue
Canada and Mexico	1.59 %	of total Revenue
Royalty	0.18 %	of total Revenue
Royalty Canada and Mexico AbbVie Plc	0.62 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Ironwood Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

The Hatch-Waxman Act establishes the regulatory framework for marketing and distributing generic drugs in the United States. It permits generic drug manufacturers to submit abbreviated new drug applications (ANDAs) to the U.S. Food and Drug Administration (FDA), relying on prior safety and effectiveness data of brand-name drugs. The Act grants market exclusivity periods to encourage drug development, including five years for new chemical entities and three years for certain new clinical investigations related to approved drugs. These exclusivity periods prevent approval of competing generic drugs for specified conditions during the protected timeframe. Additionally, new drug application (NDA) applicants must provide patent information for listing in the FDA's Orange Book, and ANDA or 505(b)(2) applicants are required to submit certifications concerning these patents.

Ironwood Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers

IRWD's Stock Performance relative to it's Customers

IRWD's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Ironwood Pharmaceuticals inc	685.43	361.51	102.18	100
SUBTOTAL	0.00	0.00	0.00	-

Sources: Ironwood Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ironwood Pharmaceuticals inc’s corporate clients.
For your research, we’ve provided 9 tables on Ironwood Pharmaceuticals inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.